system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Alkaloids, Animals, Antineoplastic Agents, Apoptosis, Benzodioxoles, Cell Cycle, Cell Line, Tumor, Cell Proliferation, Cell Survival, Disease Models, Animal, Drug Synergism, Female, Humans, Inhibitor of Apoptosis Proteins, Mice, Phosphorylation, Piperidines, Polyunsaturated Alkamides, Survivin, TNF-Related Apoptosis-Inducing Ligand, Transcription Factor RelA, Triple Negative Breast Neoplasms, Tumor Burden.
user
Does piperine enhance the efficacy of TRAIL-based therapy for triple-negative breast cancer cells? Context: Triple-negative breast cancer (TNBC) is most the aggressive type of breast cancer and is poorly responsive to endocrine therapeutics; however, one of the most attractive treatments is tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-based therapies. To identify compounds that enhance the efficacy of TRAIL-based therapies, we screened 55 compounds from natural products in combination with TRAIL in TNBC cells. Human TNBC cells, MDA-MB-468 and MDA-MB-231, and murine TNBC cells, 4T1, were used. Cell viability, apoptotic cells, and cell cycle were quantified by the WST-1 assay, annexin-V/7-amino-actinomycinD (7-AAD) staining and Propidium iodide (PI) staining, respectively. In vivo effects of piperine were evaluated in the orthotopic-inoculated 4T1-luc mouse model. After screening, we identified piperine as the most potent adjuvant at enhancing the efficacy of TRAIL-based therapies in TNBC cells in vitro and in vivo, which might be mediated through inhibition of survivin and p65 phosphorylation.
assistant
Piperine may enhance TRAIL-based therapeutics for TNBC. Final Decision: yes